EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Corporativo Fragua S.A.B. de C.V (FRAGUAB) fair value: what the stock is really worth

We calculate from audited financials what Corporativo Fragua S.A.B. de C.V is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · MX · ISIN MXP321131015

CF Some data Sep 13, 2026

Corporativo Fragua S.A.B. de C.V

FRAGUAB · MX

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

Fair value 720.69 MXN · Strongly undervalued (+68%)
!Quality 53/100
!Mixed Growth (revenue 5y +14.2 %/yr)
!Thin margins · 3.3% net margin (TTM)
Low debt · generates free cash flow
Ranks above peers (11/14)
!Moderate moat 47/100
!Insider activity 30/100
!Evidence only medium, so the estimate is less certain
Watch Corporativo Fragua S.A.B. de C.V for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

982.73 MXN 270.33 MXN Fair Value 720.69 MXN Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range 270.33 MXN – 982.73 MXN · fair‑value band 370.27 MXN – 1,139 MXN · the 429.83 MXN price screens below the 720.69 MXN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Corporativo Fragua, S.A.B. de C.V., together with its subsidiaries, operates pharmacy stores in Mexico. The company purchases and sells medicine products, perfumes, photography equipment, household goods, food, miscellaneous items, and others.

Show more

Corporativo Fragua, S.A.B. de C.V., together with its subsidiaries, operates pharmacy stores in Mexico. The company purchases and sells medicine products, perfumes, photography equipment, household goods, food, miscellaneous items, and others. It is also involved in the provision of maintenance and surveillance services, and medical services; operation service of distribution centers; management, logistics, and personnel services; maintenance and repair of furniture; transport and distribution of goods; purchase, sale, and rental of buildings; and manufacture and packaging of non-alcoholic beverages. The company was founded in 1942 and is based in Guadalajara, Mexico.

Stock analysis

Corporativo Fragua S.A.B. de C.V (FRAGUAB) currently trades at 429.83 MXN, while our model-based Fair Value estimate is 720.69 MXN, implying the stock looks roughly 40.4% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 1,075 MXN per share, and 19 of the 25 models we run sit above the 429.83 MXN price.

Bear case: the Growth DCF group reads lowest at 77.16 MXN, and 6 of the 25 models stay below the price. Evidence for this calculation is medium.

Scenario range: 370.27 MXN (bear) to 1,139 MXN (bull), the price of 429.83 MXN sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Corporativo Fragua S.A.B. de C.V reported revenue of 120B MXN in FY2024 versus 73.3B MXN in FY2020, a compound +13.2%/yr. Reported net income was 4.9B MXN in FY2024, compounding +24.7%/yr from FY2020.

Key figures

Market cap 41.6B MXN (≈ $2.4B) · P/E ratio 8.9 · P/S ratio 0.36 · EPS (TTM) 47.76 MXN · Net margin 4.1% · Return on equity 16.1% · Return on assets (EBIT) 8.0% · Operating margin 5.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 30% below its 52-week high, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 68%, FRAGUAB screens cheaper than that median.

Fair Value models

Bear 370.27 MXN Fair Value 720.69 MXN Bull 1,139 MXN
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2024 figures (about 12 months old). Earnings retained since then (47.80 MXN per share) are deliberately not added. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 70.55 MXN 78.20 MXN 92.25 MXN 82
Growth DCF 70.40 MXN 77.16 MXN 89.09 MXN 80
EPV 303.51 MXN 343.71 MXN 378.88 MXN 74
All 25 models by family
DCF Models
FCF DCF 70.55 MXN 78.20 MXN 92.25 MXN 82
Owner Earnings 324.35 MXN 568.61 MXN 1,018 MXN 73
5Y Revenue Exit 384.80 MXN 752.26 MXN 1,283 MXN 70
5Y EBITDA Exit 486.37 MXN 970.30 MXN 1,613 MXN 72
5Y P/E Exit 587.35 MXN 1,187 MXN 1,912 MXN 68
10Y Revenue Exit 265.82 MXN 583.10 MXN 1,130 MXN 63
10Y EBITDA Exit 350.90 MXN 746.66 MXN 1,417 MXN 64
10Y P/E Exit 419.00 MXN 909.29 MXN 1,678 MXN 60
Earnings-Based
Graham-Dodd 348.16 MXN 1,845 MXN 2,555 MXN 63
Lynch FV 508.21 MXN 726.02 MXN 943.83 MXN 61
PEG = 1.0 508.21 MXN 726.02 MXN 943.83 MXN 57
EPV 303.51 MXN 343.71 MXN 378.88 MXN 74
Dividend Discount
Gordon GGM 120.26 MXN 250.05 MXN 396.67 MXN 66
DDM Multi-Stage 120.26 MXN 210.85 MXN 262.43 MXN 66
Multiples
P/E Multiple 806.41 MXN 1,075 MXN 1,344 MXN 63
P/S Multiple 652.80 MXN 870.41 MXN 1,088 MXN 58
P/B Multiple 652.80 MXN 870.41 MXN 1,088 MXN 55
EV/EBIT 708.06 MXN 923.30 MXN 1,139 MXN 66
EV/EBITDA 712.89 MXN 929.74 MXN 1,147 MXN 67
EV/Revenue 523.21 MXN 720.72 MXN 918.24 MXN 54
Asset-Based
NCAV (Graham) 132.72 MXN 177.85 MXN 265.44 MXN 54
Growth DCF
Growth DCF 70.40 MXN 77.16 MXN 89.09 MXN 80
Economic Profit
Residual Income 337.81 MXN 451.43 MXN 1,826 MXN 64
ROIC Compounder 324.73 MXN 430.49 MXN 542.22 MXN 72
Growth Earnings
Growth-Adj P/E 752.35 MXN 1,075 MXN 1,397 MXN 67

Open the full fair value analysis →

Notify me when FRAGUAB reaches fair value

Put FRAGUAB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 54 · Market factors (momentum, volatility) 41

Profitability 69
Margins and returns on capital today
Quality Growth 44
Are margins and returns improving?
Cashflow 18
Earnings quality: real cash, not paper profit
Fin. Strength 65
Balance sheet, leverage, solvency risk
Investment 51
Disciplined investing over empire-building
Low Volatility 88
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 84
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+9.9%
Revenue growth 3 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
Revenue growth 24 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
What shareholders gained per year (last 5 years), in MXN (mathematically smoothed) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in MXN: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+23.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.8%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 4%
2024 sits 62% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price
What the price assumes This turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

Watch FRAGUAB, get fair value alerts →

Compare Corporativo Fragua S.A.B. de C.V with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 59 stocks

Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside +65% · Top 25%
Profitability
Return on equity (TTM) 16% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 3% · Top 25%
Operating margin (TTM) 6% · Top 25%
Growth and dividend
Revenue growth 7% · Above median
Dividend yield (TTM) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Below median

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 8.9× · Cheapest 25%
P/B 1.75× · Pricier than median
P/S (TTM) 0.33× · Cheaper than median
P/FCF 45.7× · Priciest 25%
EV/EBITDA 4.5× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 27
FUTURE (revenue growth)33 · sector 23
PAST (return on equity)64 · sector 15
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 67

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Yifeng Pharmacy Chain Co 603939 ¥22.78 ¥40.59 +78%
DaShenLin Pharmaceutical Group 603233 ¥18.38 ¥26.45 +44%
MedPlus Health Services Limited MEDPLUS ₹660.40 ₹193.68 −71%
LBX Pharmacy Chain Joint Stock Company 603883 ¥12.48 ¥13.73 +10%
Yixintang Pharmaceutical Group 002727 ¥10.89 ¥9.51 −13%
Anhui Huaren Health Pharmaceutical Co 301408 ¥13.70 ¥15.07 +10%
ShuYu Civilian Pharmacy Corp 301017 ¥12.07 ¥5.91 −51%
Apotea AB APOTEA kr 74.00 kr 46.46 −37%
Luyan Pharma Co 002788 ¥10.63 ¥15.91 +50%
DocMorris AG DOCM CHF 10.00 CHF 1.65 −84%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Corporativo Fragua S.A.B. de C.V Fair Value". https://www.fairvalue-calculator.com/stock/FRAGUAB

Frequently asked questions

Is Corporativo Fragua S.A.B. de C.V (FRAGUAB) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 720.69 MXN versus a price of 429.83 MXN, about +68% upside (undervalued).
What is the fair value of FRAGUAB?
Our model-based fair value for Corporativo Fragua S.A.B. de C.V is 720.69 MXN (as of Sep 13, 2026), built from audited fundamentals. The current price: 429.83 MXN.
What is the quality score of FRAGUAB?
Corporativo Fragua S.A.B. de C.V has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
Our model-based price target is the fair value of 720.69 MXN (as of Sep 13, 2026) from 25 valuation models. Cautious scenario 370.27 MXN, optimistic scenario 1,139 MXN. It is a calculation from audited fundamentals, not an analyst target.
What is the Corporativo Fragua S.A.B. de C.V stock forecast for 2026?
Our models put fair value at 720.69 MXN, about +68% upside versus a price of 429.83 MXN (undervalued). Cautious scenario 370.27 MXN, optimistic scenario 1,139 MXN. The calculation is refreshed regularly with new filings.
What is the revenue of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
Corporativo Fragua S.A.B. de C.V reported trailing-twelve-month revenue of about 134B MXN (latest available figure, as of Sep 13, 2026).
What growth is priced into Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
For today's price to be fair in a discounted-cash-flow model, Corporativo Fragua S.A.B. de C.V would have to grow free cash flow by more than 80 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.2 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of FRAGUAB use?
Our models discount Corporativo Fragua S.A.B. de C.V at 10.5 %: a base by market capitalisation (mid), damped by beta 0.09, country premium for Mexico. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Corporativo Fragua S.A.B. de C.V that is more than 80 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Corporativo Fragua S.A.B. de C.V (FRAGUAB) delivered so far?
Over the past 5 years revenue at Corporativo Fragua S.A.B. de C.V grew +14.2 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Corporativo Fragua S.A.B. de C.V (FRAGUAB) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into Corporativo Fragua S.A.B. de C.V (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
The free-cash-flow yield on the price is 0.14 %: that much free cash flow Corporativo Fragua S.A.B. de C.V produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corporativo Fragua S.A.B. de C.V it is 720.69 MXN per share (as of Sep 13, 2026), against a price of 429.83 MXN. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Corporativo Fragua S.A.B. de C.V stock overvalued or undervalued in 2026?
As of Sep 13, 2026, FRAGUAB trades below its calculated fair value: price 429.83 MXN, fair value 720.69 MXN, a gap of about +68% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of FRAGUAB?
No. The price is what the market pays today (429.83 MXN); the fair value is what the company's own numbers justify (720.69 MXN). For Corporativo Fragua S.A.B. de C.V the two are 290.86 MXN per share apart. That gap is exactly why we show both numbers side by side.
How much is Corporativo Fragua S.A.B. de C.V worth?
The market values Corporativo Fragua S.A.B. de C.V at about 41.6B MXN (market capitalisation, as of Sep 13, 2026). Per share that is 429.83 MXN; our models calculate a fair value of 720.69 MXN per share.
What do the bullish and bearish scenarios say about FRAGUAB?
Our models span a range for Corporativo Fragua S.A.B. de C.V: cautious scenario 370.27 MXN, base 720.69 MXN, optimistic 1,139 MXN per share (as of Sep 13, 2026, price 429.83 MXN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of FRAGUAB?
Corporativo Fragua S.A.B. de C.V trades at a price-to-earnings ratio of 8.9 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 720.69 MXN is built from several models across several years. Other multiples: P/B 1.8, P/S 0.3, EV/EBITDA 4.5.
How solid is the balance sheet of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
Balance-sheet figures for Corporativo Fragua S.A.B. de C.V (as of Sep 13, 2026): return on equity 16.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is FRAGUAB from its 52-week high?
Corporativo Fragua S.A.B. de C.V trades at 429.83 MXN, about 30% below its 52-week high of 611.91 MXN (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 720.69 MXN is for.
Which stocks are comparable to Corporativo Fragua S.A.B. de C.V?
From the same area (Healthcare) we also value Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, MedPlus Health Services Limited, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corporativo Fragua S.A.B. de C.V stock attractive at the current price?
The data as of Sep 13, 2026: price 429.83 MXN, calculated fair value 720.69 MXN (+68%), Quality Score 53/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of FRAGUAB calculated?
We run Corporativo Fragua S.A.B. de C.V through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 720.69 MXN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.0 % above its aggregate fair value. Corporativo Fragua S.A.B. de C.V currently trades 68 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
The closing price on Sep 18, 2026 was 429.83 MXN. Our model-based fair value is 720.69 MXN, about +68% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corporativo Fragua S.A.B. de C.V right now?
The model range is unusually wide (370.27 MXN to 1,139 MXN). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Corporativo Fragua S.A.B. de C.V

How large is the market capitalisation of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
The market capitalisation of Corporativo Fragua S.A.B. de C.V is 41.6B MXN (≈ $2.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
The price-to-sales ratio of Corporativo Fragua S.A.B. de C.V is 0.36 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
Earnings per share at Corporativo Fragua S.A.B. de C.V are 47.76 MXN (price ÷ EPS = P/E 8.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
The net margin of Corporativo Fragua S.A.B. de C.V is 4.1% (fiscal year 2024). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
The return on equity (ROE) of Corporativo Fragua S.A.B. de C.V is 16.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
On an EBIT basis the return on assets of Corporativo Fragua S.A.B. de C.V is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
The operating margin of Corporativo Fragua S.A.B. de C.V is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
Revenue at Corporativo Fragua S.A.B. de C.V is growing +6.5% versus a year earlier (3y avg +12.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Corporativo Fragua S.A.B. de C.V (FRAGUAB)?
Earnings per share at Corporativo Fragua S.A.B. de C.V are growing −2.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Corporativo Fragua S.A.B. de C.V in the live analysis

One click puts Corporativo Fragua S.A.B. de C.V on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.